Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Appointment of Interim CFO

21 November 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive Officer, Manuel Llobet.

Martin brings significant financial experience across multiple industries. He served as CFO of Novasep SA, a supplier of pharmaceuticals and biopharmaceuticals, and during his tenure Novasep won a major contract with AstraZeneca to support the large-scale production of the active substance of its adenovirus vector-based COVID-19 vaccine. Martin previously served as CFO of formerly listed Cambian Group plc, a provider of specialist residential and educational services for children and young adults, and of Consort Medical plc, a medical devices company.

The appointment of Martin Hopcroft follows the announcement on 26 May 2022 that Nick Wykeman, CFO, will leave Allergy Therapeutics on 30 November 2022 to pursue non-executive roles. The Group is continuing its search for a permanent CFO and will make a further announcement in due course.

Manuel Llobet, Chief Executive Officer, commented: "Martin is a highly experienced executive and it is my pleasure to welcome him to Allergy Therapeutics' senior management team. I also want to take this opportunity to again thank Nick Wykeman for his work and dedication over the past six years and I wish him the very best for his future."

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.